[
    [
        {
            "time": "",
            "original_text": "失效的“ 周期股避险共识”：明星基金经理三寻新方向",
            "features": {
                "keywords": [
                    "周期股",
                    "避险共识",
                    "明星基金经理"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "周期股"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "失效的“ 周期股避险共识”：明星基金经理三寻新方向",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "健帆生物（300529）一季报点评：业绩符合我们预期，看好公司中长期发展【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "健帆生物",
                    "一季报",
                    "业绩",
                    "中长期发展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物（300529）一季报点评：业绩符合我们预期，看好公司中长期发展【东吴医药朱国广团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "中国银河-健帆生物：业绩高速增长，血灌产品快速放量【公司研究】",
            "features": {
                "keywords": [
                    "健帆生物",
                    "业绩",
                    "高速增长",
                    "血灌产品",
                    "快速放量"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中国银河-健帆生物：业绩高速增长，血灌产品快速放量【公司研究】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]